Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Once-weekly combined cagrilintide 2.4 mg and semaglutide 2.4 mg were tied to reductions in blood pressure and improvements in ...

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond ...

Danish pharma major Novo Nordisk (NOV: N) has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating CagriSema (cagrilintide/semaglutide), an investigational injectable ...

CagriSema was associated with significant reductions in blood pressure relative to the medications alone among patients with ...

CagriSema may redefine Novo Nordisk’s position in the industry. Learn why investors and analysts are watching this secret weapon closely.

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial ...

When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical program is ongoing to ...

A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications ...

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss ...